Literature DB >> 30049377

Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation.

Sara Baglivo1, Biagio Ricciuti2, Vienna Ludovini2, Giulio Metro2, Annamaria Siggillino2, Andrea De Giglio2, Rita Chiari2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30049377     DOI： 10.1016/j.jtho.2018.03.017

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  4 in total

Review 1.  Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.

Authors:  Yuan Cheng; Tao Zhang; Qing Xu
Journal:  MedComm (2020)       Date:  2021-12-14

2.  Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report.

Authors:  Zhan Wang; Yan Geng; Ling-Yan Yuan; Miao-Miao Wang; Chen-Yang Ye; Li Sun; Wei-Ping Dai; Yuan-Sheng Zang
Journal:  Front Oncol       Date:  2022-02-14       Impact factor: 6.244

3.  Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.

Authors:  Ken Takahashi; Yosuke Seto; Koutaroh Okada; Shinya Uematsu; Ken Uchibori; Mika Tsukahara; Tomoko Oh-Hara; Naoya Fujita; Noriko Yanagitani; Makoto Nishio; Kenichi Okubo; Ryohei Katayama
Journal:  Thorac Cancer       Date:  2020-01-13       Impact factor: 3.500

Review 4.  Tyrosine Kinase Receptors in Oncology.

Authors:  Jorge Esteban-Villarrubia; Juan José Soto-Castillo; Javier Pozas; María San Román-Gil; Inmaculada Orejana-Martín; Javier Torres-Jiménez; Alfredo Carrato; Teresa Alonso-Gordoa; Javier Molina-Cerrillo
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.